# 510(k) Summary

This summary of the $5 1 0 ( { \sf k } )$ safety and effectivenessinformation s being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.   
The assigned 510(k) number is: K0734/90

1Submitter name, address, contact

<table><tr><td>Olympus America Inc. 3500 Corporate</td></tr><tr><td>Parkway Center Valley, PA 18034</td></tr><tr><td>U.S. Telephone: 469-230-0959</td></tr><tr><td>U.S. Fax: 972-317-7861</td></tr><tr><td>Contact Person: Stephanie G. Donnelly</td></tr><tr><td>Date Prepared: December 10, 2007</td></tr><tr><td>Proprietary Name: Olympus IgG Reagent (OSR6X172)</td></tr><tr><td>Common Name: IgG Reagent</td></tr><tr><td>Classification Name: IgG, Antigen, Antiserum, Control</td></tr><tr><td>Serum/Plasma Olympus (OSR6145) IgG Reagent Applications Submitted (K951013)</td></tr><tr><td>CSF Application Roche Tina-Quant IgG GEN.2 Submitted (K050113)</td></tr></table>

Device name

Predicate device(s)

Device description

In this Olympus procedure:

When a sample is mixed with R1 buffer and R2 antiserum solution, human IgG reacts specifically with anti-human IgG antibodies to yield insoluble aggregates.   
Immune complexes forrned in solution scatter light in   
proportion to their size, shape and concentration.   
Turbidimeters measure the reduction of incidence light due to reflection, absorption or scatter.   
In the Olympus procedure, the decrease in intensity of light transmitted (increase in absorbance) through particles suspended in solution is as a result of complexes formed during the antigen-antibody reaction.

5. Intended use

System reagent for the quantitative determination of lgG immunoglobulins in human serum, plasma and cerebrospinal fluid on OLYMPUS analyzers.

For in vitro diagnostic use.

# Serum/Plasma Applications

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Olympus IgG (OSR6X172) reagent</td><td rowspan=1 colspan=1>Predicate System</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>System reagent for the quantitativedetermination of IgG immunoglobulinsin human serum, plasma andcerebrospinal fluid on OLYMPUSanalyzers.</td><td rowspan=1 colspan=1>System reagent for the quantitativedetermination of IgG immunoglobulinsin human serum on OLYMPUSanalyzers.</td></tr><tr><td rowspan=1 colspan=1>Measurement</td><td rowspan=1 colspan=1>Quantitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Instrument Required</td><td rowspan=1 colspan=1>Olympus AU400/400®, 600/640/640®and 2700/5400</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent handling</td><td rowspan=1 colspan=1>Ready for use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AssayMethodology/OperatingPrinciple</td><td rowspan=1 colspan=1>Immunoturbidimetric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent storage form</td><td rowspan=1 colspan=1>LiquidOn -board storage</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Olympus Serum Protein Mulit-Calibrator (ODR3021)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Traceability</td><td rowspan=1 colspan=1>This method is traceable to theIntemational Reference Preparation CRM470 (US designation RPPHS lot 91/0619)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Goat Anti-igG antiserum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>635-1741 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent On Board Stability</td><td rowspan=1 colspan=1>Opened reagents are stable for 90days when stored in the refrigeratedcompartment of the analyzer.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Frequency</td><td rowspan=1 colspan=1>90 days</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Olympus IgG (OSR6X172) reagent</td><td rowspan=1 colspan=1>Predicate System</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Serum, Li-heparin or EDTA plasma:and cerebrospinal fluid</td><td rowspan=1 colspan=1>Serum</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Performance Characteristics</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Olympus IgG (OSR6X172) reagent</td><td rowspan=1 colspan=1>Predicate System</td></tr><tr><td rowspan=1 colspan=1>Assay Range</td><td rowspan=1 colspan=1>75-3000 mg/dL</td><td rowspan=1 colspan=1>75-3000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>LOQ</td><td rowspan=1 colspan=1>75 mg/dL</td><td rowspan=1 colspan=1>Not specified</td></tr><tr><td rowspan=1 colspan=1>Prozone Capacity</td><td rowspan=1 colspan=1>No high dose effect at IgGconcentrations up to 30,000 mg/dL</td><td rowspan=1 colspan=1>Not specified</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>AU400/400^$Sample      Total CV%1            2.182            2.293            3.43AU600/640/640Sample      Total CV%1            3.292            3.493            4.66</td><td rowspan=1 colspan=1>AU400/400Sample      Total CV%1             0.822            1.063            2.24AU600Sample      Total CV%-NM            2.501.541.92</td></tr></table>

<table><tr><td></td><td>AU2700/5400 Sample Total CV% 1 1.51 2 1.87 3 2.03</td><td>AU640/640 Sample 1 2 AU2700/5400 Sample 1 2 3</td><td>Total CV% 1.00 1.00 Total CV% 1.54 2.39</td></tr><tr><td>Method Comparison (Linear Regression)</td><td>Intercept 37.2 Slope 0.945 R^{}$ 0.998 n 120 Range 195-2986 mg/dL</td><td>intercept Slope $R^{2}$ n Range</td><td>2.84 -117 1.086 0.993 98 223-2633 mg/dL</td></tr><tr><td>Interfering Substances</td><td>AU400/400® Bilirubin: Interference less than 2% up to 40 mg/dL. Bilirubin Hemolysate: Interference less than 3% up to 500 mg/dL Hemolysate Lipemia: Interference less than 3% up to 1000 mg/dL Intralipid</td><td>AU400/400® Bilirubin: Interference less than 1% up to 40 mg/dL Bilirubin Hemolysis: Interference less than 2% up to 500 mg/dL Hemolysate Lipemia: Interference less than/10% up to 1000 mg/dL Intralipid.</td><td></td></tr><tr><td></td><td>RF: Interferences less than 7% up to 1200 IU/mL</td><td>RF: Not Specified</td><td></td></tr><tr><td></td><td>Not tested AU600/640/640</td><td>Ascorbic acid: Interference less than 1% up to 20 mg/dL Ascorbate</td><td></td></tr><tr><td></td><td>Bilirubin: Interference less than 3% up to 40 mg/dL Bilirubin Hemolysate: Interference less than 3%</td><td>AU600/640/640® Bilirubin: Interference less than 2% up to 40 mg/dL Bilirubin</td><td></td></tr><tr><td></td><td>up to 500 mg/dL Hemolysate Lipemia: Interference less than 5% up to 1000 mg/dL Intralipid</td><td>Hemolysis: Interference less than 2% up to 500 mg/dL Hemolysate Lipemia: Interference less than 3% up to 1000 mg/dL Intralipid.</td><td></td></tr><tr><td></td><td>RF: Interferences less than 7% up to 1200 IU/mL</td><td>RF: Not Specified</td><td></td></tr><tr><td></td><td>Not tested</td><td></td><td></td></tr><tr><td></td><td></td><td>Ascorbic acid: Interference less than</td><td></td></tr><tr><td></td><td></td><td>2% up to 20 mg/dL Ascorbate</td><td></td></tr><tr><td></td><td>AU2700/5400 Bilirubin: Interference less than 1% up</td><td>AU2700/5400</td><td></td></tr><tr><td></td><td>to 40 mg/dL Bilirubin</td><td>to 40 mg/dL Bilirubin</td><td>Bilirubin: Interference less than 5% up</td></tr><tr><td></td><td>Hemolysate: Interference less than 3% up to 500 mg/dL Hemolysate</td><td></td><td>Hemolysis: Interference less than 3%</td></tr><tr><td></td><td>Lipemia: Interference less than 2% up</td><td>up to 500 mg/dL. Hemolysate</td><td>Lipemia: Interference less than 3% up</td></tr><tr><td></td><td>to 1000 mg/dL Intralipid</td><td>to 1000 mg/dl Intralipid.</td><td></td></tr><tr><td></td><td>RF: Interferences less than 7% up to</td><td></td><td></td></tr><tr><td></td><td>1200 IU/mL</td><td>RF: Not Specified</td><td></td></tr><tr><td></td><td></td><td>Ascorbic acid: Interference less than</td><td></td></tr><tr><td>Not tested</td><td></td><td>3% up to 20 mg/dL Ascorbate</td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr></table>

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Olympus IgG (OSR6X172) reagent</td><td rowspan=1 colspan=1>Predicate Systems</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>System reagent for the quantitativedetermination of IgG immunoglobulinsin human serum, plasma andcerebrospinal fluid on OLYMPUSanalyzers.</td><td rowspan=1 colspan=1>In vitro test for the quantitative determinationof IgG in human serum, plasma andcerebrospinal on Roche/Hitachi Cobas csystems.1</td></tr><tr><td rowspan=1 colspan=1>Measurement</td><td rowspan=1 colspan=1>Quantitative</td><td rowspan=1 colspan=1>Same                  :</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Serum, plasma: Li-heparin or EDTAand cerebrospinal fluid</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Goat Anti-IgG antiserum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent handling</td><td rowspan=1 colspan=1>Ready for use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AssayMethodology/OperatingPrinciple</td><td rowspan=1 colspan=1>Immunoturbidimetric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent storage form</td><td rowspan=1 colspan=1>LiquidOn -board storage</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Traceability</td><td rowspan=1 colspan=1>CRM 470</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Multi-point   -</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Olympus IgG (OSR6X172) reagent</td><td rowspan=1 colspan=1>Predicate System</td></tr><tr><td rowspan=1 colspan=1>Instrument Required</td><td rowspan=1 colspan=1>Olympus AU400/400®, 600/640/640®and 2700/5400</td><td rowspan=1 colspan=1>Roche/Hitachi Cobas c systems.</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>15 - 20 y 3.5 mg/dL ± 2.0 mg/dl.21 - 40 y 4.2 mg/dL ± 1.4 mg/dl.41 - 60 y 4.7 mg/dL ± 1.0 mg/dl</td><td rowspan=1 colspan=1>1-3 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Reagent On Board Stability</td><td rowspan=1 colspan=1>Opened reagents are stable for 90 dayswhen stored in the refrigeratedcompartment of the analyzer.</td><td rowspan=1 colspan=1>Opened reagents are stable for 84 dayswhen stored in the refrigerated compartmentof the analyzer.</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Olympus Serum Protein Mulit-Calibrator (ODR3021)</td><td rowspan=1 colspan=1>S1 H2OS2 C.f.a.s. PUC</td></tr><tr><td rowspan=1 colspan=1>Calibration Frequency</td><td rowspan=1 colspan=1>2 Days</td><td rowspan=1 colspan=1>Not Specified</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Performance Characteristics</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Olympus IgG (OSR6X172) reagent</td><td colspan="1" rowspan="1">Predicate System</td></tr><tr><td colspan="1" rowspan="1">Assay Range</td><td colspan="1" rowspan="1">2-50 mg/dl</td><td colspan="1" rowspan="1">0.4-20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">LoQ</td><td colspan="1" rowspan="1">2 mg/dL</td><td colspan="1" rowspan="1">Not specified</td></tr><tr><td colspan="1" rowspan="1">Prozone Capacity</td><td colspan="1" rowspan="1">No high dose effect at IgGconcentrations up to 6,000 mg/dL</td><td colspan="1" rowspan="1">No high dose effect at IgG concentrations upto 100 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Precision</td><td colspan="1" rowspan="1">AU400/400®Sample      Total CV%1            9.822            4.083             3.61AU600/640/640*Sample      Total CV%1             9.532            3.673             2.81AU2700/5400Sample      Total CV%1             10.242            6.293            3.83</td><td colspan="1" rowspan="1">Sample      Total CV%1            2.12            1.1</td></tr><tr><td></td><td></td><td></td></tr><tr><td>Method Comparison (Linear Regression)</td><td>Intercept -0.069 Slope 1.067 R^{2 }$ 0.998 Range 2.0-42.9 mg/dL</td><td>Intercept -0.17 Slope 0.997 R^2}$ 1.000 Range 1.07-18.6 mg/dL</td></tr><tr><td>Interfering Substances</td><td>AU400/400/600/640/640®/2700/5400 Bilirubin: Interference less than 10% up to 36 mg/dL Bilirubin Hemolysis: Interference less than 10% up to 500 mgdL Hemolysate</td><td>Bilirubin: Interference less than 10% up to 15 mg/dL. Bilirubin Hemolysis: Interference less than 10% up to 200 mg/dL Hemolysate</td></tr></table>

# FEB 11 2008

Olympus America, Inc.   
c/o Ms. Stephanie Donnelly   
Regulatory Affairs/Quality Assurance Manager Olympus Life Science Research Europa GmbH Lismeehan, O, Callaghan's Mills   
Co. Claire, Ireland.

Re: k073490 Trade/Device Name: Olympus IgG reagent Regulation Number: 21 CFR 866.5510 Regulation Name: Immunoglobulins A, G, M, D, E immunological test systems Regulatory Class: Class II Product Code: CFN Dated: December 11, 2007 Received: December 12, 2007

Dear Ms. Donnelly:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (or the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (MA), it may be subject to such additional controls.Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter willallow you to begin marketing your device as described in your Section 510(k) premarket notification. The

Page 2 -

FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

PobeBecke

Robert L. Becker, Jr. M.D., Ph.I.   
Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

# Indication for Use

510(k) Number (if known): K073490

Device Name: The Olympus IgG reagent (OSR6X172).

Indication For Use: System reagent for the quantitative determination of IgG immunoglobulins in human serum, plasma and cerebrospinal fluid on OLYMPUS analyzers.

The measurement of IgG aids in the diagnosis of abnormal protein metabolism and the body's lack of ability to resist infectious agents.

For in vitro diagnostic use.

# Concurrence of CDRH, Offce of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/39cf6b31678febe67759ff55901077a5eb98996d8391f494c1b4c9b431cad144.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K073490